(C) Reuters. Is Biogen a Buy, Sell, or Hold?
Pharmaceutical developer Biogen (BIIB) is making substantial progress in its research, which is driving a gradual rise in its share price. However, will the company be able to survive despite a continued decline in its financials? Read more to find out.Pharmaceutical company Biogen Inc. (NASDAQ:BIIB) is one the leading companies in the biopharma space, with a market capitalization of $40.77 billion. The stock has gained 11.6% year-to-date, following its 19.5% decline over the past year.
BIIB has been gaining momentum owing to its breakthrough research in multiple spheres. However, the company’s bleak growth outlook is a cause for concern.
Click here to checkout our Healthcare Sector Report for 2021
Is Biogen a Buy, Sell, or Hold?
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.